Researchers find seasonal variations in risk of hypertensive disorders during pregnancy

Researchers find seasonal variations in risk of hypertensive disorders during pregnancy

Researchers observed seasonal variations in the risk of the hypertensive disorders of pregnancy--including gestational hypertension and preeclampsia--in a study of Danish women. In the Acta Obstetricia et Gynecologica Scandinavica study, the highest risk for hypertensive disorders was seen in pregnancies conceived during spring and summer. Of 50,665 women included in the study, 8.5% were diagnosed with a hypertensive disorder of pregnancy. There appeared to be increasing risk when conceiving during the spring and early summer, peaking midsummer, and subsequently decreasing steadily during the autumn to reach a low by winter. Seasonal variations in vitamin D levels may help to explain these findings. Our results are of great interest, as vitamin D may have caused the observed seasonal variation in the hypertensive disorders. It has long been assumed that vitamin D affects the pathogenesis of hypertensive disorders of pregnancy--including preeclampsia--and our results support this hypothesis." Christine Rohr Thomsen, lead author, Aarhus University Hospital, in Denmark Source: Wiley Journal reference: Thomsen, C. R., et al. (2020) Seasonal variation in the hypertensive disorders of pregnancy in Denmark. Acta Obstetricia et Gynecologica Scandinavica. doi.org/10.1111/aogs.13786 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More